YKL-40 acts as an angiogenic factor to promote tumor angiogenesis

Frontiers in Physiology

Volumn 4 MAY, Issue , 2013, Pages

  Shao, Rong ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Angiogenesis; Neutralizing anti YKL 40 antibody; Tumor cells; Tumor microenvironment; Tumor associated macrophages; Vascular endothelial cells; VEGF; YKL 40

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; FOCAL ADHESION KINASE; MAY ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN YKL 40; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; DISEASE FREE SURVIVAL; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84883786590     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00122     Document Type: Article

References (92)

1. Baird, A., Schubert, D., Ling, N., and Guillemin, R. (1988). Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc. Natl. Acad. Sci. U.S.A. 85, 2324-2328.
2. Beauvais, D. M., Burbach, B. J., and Rapraeger, A. C. (2004). The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J. Cell Biol. 167, 171-181. doi: 10.1083/jcb.200404171
3. Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603. doi: 10.1038/nrc2442
4. Bergmann, O. J., Johansen, J. S., Klausen, T. W., Mylin, A. K., Kristensen, J. S., Kjeldsen, E., et al. (2005). High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin. Cancer Res. 11, 8644-8652. doi: 10.1158/1078-0432.CCR-05-1317
5. Bernfield, M., Gotte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., et al. (1999). Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777. doi: 10.1146/annurev.biochem.68.1.729
6. Bingle, L., Brown, N. J., and Lewis, C. E. (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265. doi: 10.1002/path.1027
7. Boimel, P. J., Smirnova, T., Zhou, Z. N., Wyckoff, J., Park, H. I., Coniglio, S. J., et al. (2012). Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res. 14, R23. doi: 10.1186/bcr3108
8. Bonneh-Barkay, D., Wang, G., Starkey, A., Hamilton, R. L., and Wiley, C. A. (2010). In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J. Neuroinflamm. 7:34. doi: 10.1186/1742-2094-7-34
9. Boot, R. G., Renkema, G. H., Strijland, A., van Zonneveld, A. J., and Aerts, J. M. (1995). Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J. Biol. Chem. 270, 26252-26256. doi: 10.1074/jbc.270.44.26252
10. Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., et al. (2008). Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26, 1810-1816. doi: 10.1200/JCO.2007.14.5375
11. Casanovas, O., Hicklin, D. J., Bergers, G., and Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. In Cancer Cell, pp. 299-309. doi: 10.1016/j.ccr.2005.09.005
12. Chen, C. C., Llado, V., Eurich, K., Tran, H. T., and Mizoguchi, E. (2011a). Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells. Clin. Immunol. 140, 268-275. doi: 10.1016/j.clim.2011.04.007
13. Chen, C. C., Pekow, J., Llado, V., Kanneganti, M., Lau, C. W., Mizoguchi, A., et al. (2011b). Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia. Am. J. Pathol. 179, 1494-1503. doi: 10.1016/j.ajpath.2011.05.038
14. Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., et al. (2011c). CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19, 541-555. doi: 10.1016/j.ccr.2011.02.006
15. Chong, H., Vodovotz, Y., Cox, G. W., and Barcellos-Hoff, M. H. (1999). Immunocytochemical localization of latent transforming growth factor-beta1 activation by stimulated macrophages. J. Cell. Physiol. 178, 275-283. doi: 10.1002/(SICI)1097-4652(199903)178:3<275::AID-JCP1>3.0.CO;2-Q
16. Cintin, C., Johansen, J. S., Christensen, I. J., Price, P. A., Sorensen, S., and Nielsen, H. J. (1999). Serum YKL-40 and colorectal cancer. Br. J. Cancer 79, 1494-1499. doi: 10.1038/sj.bjc.6690238
17. Cintin, C., Johansen, J. S., Christensen, I. J., Price, P. A., Sorensen, S., and Nielsen, H. J. (2002). High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 95, 267-274. doi: 10.1002/cncr.10644
18. Coussens, L. M., and Werb, Z. (2002). Inflammation and cancer.[see comment]. Nature 420, 860-867. doi: 10.1038/nature01322
19. De Ceuninck, F., Gaufillier, S., Bonnaud, A., Sabatini, M., Lesur, C., and Pastoureau, P. (2001). YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem. Biophys. Res. Commun. 285, 926-931. doi: 10.1006/bbrc.2001.5253
20. Dubinett, S. M., Lee, J. M., Sharma, S., and Mule, J. J. (2010). Chemokines: can effector cells be redirected to the site of the tumor? Cancer J. 16, 325-335. doi: 10.1097/PPO.0b013e3181eb33bc
21. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., and Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.[see comment]. Cancer Cell 15, 232-239. doi: 10.1016/j.ccr.2009.01.021
22. Faibish, M., Francescone, R., Bentley, B., Yan, W., and Shao, R. (2011). A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol. Cancer Therap. 10, 742-751. doi: 10.1158/1535-7163.MCT-10-0868
23. Fontana, R. J., Dienstag, J. L., Bonkovsky, H. L., Sterling, R. K., Naishadham, D., Goodman, Z. D., et al. (2010). Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 59, 1401-1409. doi: 10.1136/gut.2010.207423
24. Francescone, R. A., Ngernyuang, N., Yan, W., Bentley, B., and Shao, R. (2013). Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis. Oncogene. doi: 10.1038/onc.2013.160. [Epub ahead of print].
25. Francescone, R. A., Scully, S., Faibish, M., Taylor, S. L., Oh, D., Moral, L., et al. (2011). Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 286, 15332-15343. doi: 10.1074/jbc.M110.212514
26. Fridlender, Z. G., Kapoor, V., Buchlis, G., Cheng, G., Sun, J., Wang, L. C., et al. (2011). Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am. J. Res. Cell Mol. Biol. 44, 230-237. doi: 10.1165/rcmb.2010-0080OC
27. Fusetti, F., Pijning, T., Kalk, K. H., Bos, E., and Dijkstra, B. W. (2003). Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J. Biol. Chem. 278, 37753-37760. doi: 10.1074/jbc.M303137200 pp.37753-60
28. Ganapathy, V., Ge, R., Grazioli, A., Xie, W., Banach-Petrosky, W., Kang, Y., et al. (2010). Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 9:122. doi: 10.1186/1476-4598-9-122
29. Hanahan, D., and Weinberg, R. A. (2010). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
30. Harutyunyan, M., Christiansen, M., Johansen, J. S., Kober, L., Torp-Petersen, C., and Kastrup, J. (2012). The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 217, 652-656. doi: 10.1016/j.imbio.2011.11.003
31. Hashimoto, S., Suzuki, T., Dong, H. Y., Yamazaki, N., and Matsushima, K. (1999). Serial analysis of gene expression in human monocytes and macrophages. Blood 94, 837-844.
32. Hogdall, E. V., Johansen, J. S., Kjaer, S. K., Price, P. A., Christensen, L., Blaakaer, J., et al. (2003). High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol. Rep. 10, 1535-1538.
33. Hottinger, A. F., Iwamoto, F. M., Karimi, S., Riedel, E., Dantis, J., Park, J., et al. (2011). YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann. Neurol. 70, 163-169. doi: 10.1002/ana.22360
34. Hu, B., Trinh, K., Figueira, W. F., and Price, P. A. (1996). Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J. Biol. Chem. 271, 19415-19420. doi: 10.1074/jbc.271.32.19415
35. Jensen, B. V., Johansen, J. S., and Price, P. A. (2003). High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. 9, 4423-4434.
36. Johansen, J. S., Christensen, I. J., Riisbro, R., Greenall, M., Han, C., Price, P. A., et al. (2003). High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res. Treat. 80, 15-21.
37. Johansen, J. S., Christoffersen, P., Moller, S., Price, P. A., Henriksen, J. H., Garbarsch, C., et al. (2000). Serum YKL-40 is increased in patients with hepatic fibrosis. J. Hepatol. 32, 911-920.
38. Johansen, J. S., Schultz, N. A., and Jensen, B. V. (2009). Plasma YKL-40: a potential new cancer biomarker? Future Oncol. 5, 1065-1082. doi: 10.2217/fon.09.66
39. Junker, N., Johansen, J. S., Andersen, C. B., and Kristjansen, P. E. (2005a). Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 48, 223-231. doi: 10.1016/j.lungcan.2004.11.011
40. Junker, N., Johansen, J. S., Hansen, L. T., Lund, E. L., and Kristjansen, P. E. (2005b). Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 96, 183-190. doi: 10.1111/j.1349-7006.2005.00026.x
41. Kawada, M., Seno, H., Kanda, K., Nakanishi, Y., Akitake, R., Komekado, H., et al. (2012). Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 31, 3111-3123. doi: 10.1038/onc.2011.498
42. Kim, S. H., Das, K., Noreen, S., Coffman, F., and Hameed, M. (2007). Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J. Surg. Oncol. 5:17. doi: 10.1186/1477-7819-5-17
43. Kjaergaard, A. D., Bojesen, S. E., Johansen, J. S., and Nordestgaard, B. G. (2010). Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann. Neurol. 68, 672-680. doi: 10.1002/ana.22220
44. Kronborg, G., Ostergaard, C., Weis, N., Nielsen, H., Obel, N., Pedersen, S. S., et al. (2002). Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand. J. Infect. Dis. 34, 323-326. doi: 10.1080/00365540110080233
45. Kucur, M., Isman, F. K., Balci, C., Onal, B., Hacibekiroglu, M., Ozkan, F., et al. (2008). Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol. Oncol. 26, 47-52. doi: 10.1016/j.urolonc.2007.07.020
46. Kyrgios, I., Galli-Tsinopoulou, A., Stylianou, C., Papakonstantinou, E., Arvanitidou, M., and Haidich, A. B. (2012). Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Metabolism. 61, 562-568. doi: 10.1016/j.metabol.2011.09.004
47. Kzhyshkowska, J., Gratchev, A., and Goerdt, S. (2007). Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark. Insights 2, 128-146.
48. Lee, C. G., Da Silva, C. A., Dela Cruz, C. S., Ahangari, F., Ma, B., Kang, M. J., et al. (2011). Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 73, 479-501. doi: 10.1146/annurev-physiol-012110-142250
49. Lee, C. G., Da Silva, C. A., Lee, J. Y., Hartl, D., and Elias, J. A. (2008). Chitin regulation of immune responses: an old molecule with new roles. Curr. Opin. Immunol. 20, 684-689. doi: 10.1016/j.coi.2008.10.002
50. Lee, C. G., Hartl, D., Lee, G. R., Koller, B., Matsuura, H., Da Silva, C. A., et al. (2009). Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J. Exp. Med. 206, 1149-1166. doi: 10.1084/jem.20081271
51. Leek, R. D., Hunt, N. C., Landers, R. J., Lewis, C. E., Royds, J. A., and Harris, A. L. (2000). Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 190, 430-436. doi: 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6
52. Leek, R. D., Lewis, C. E., Whitehouse, R., Greenall, M., Clarke, J., and Harris, A. L. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625-4629.
53. Lewis, C. E., and Pollard, J. W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612. doi: 10.1158/0008-5472.CAN-05-4005
54. Libreros, S., Garcia-Areas, R., Shibata, Y., Carrio, R., Torroella-Kouri, M., and Iragavarapu-Charyulu, V. (2012). Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model. Int. J. Cancer 131, 377-386. doi: 10.1002/ijc.26379
55. Malinda, K. M., Ponce, L., Kleinman, H. K., Shackelton, L. M., and Millis, A. J. (1999). Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp. Cell Res. 250, 168-173. doi: 10.1006/excr.1999.4511
56. McQuade, K. J., Beauvais, D. M., Burbach, B. J., and Rapraeger, A. C. (2006). Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts. J. Cell Sci. 119, 2445-2456. doi: 10.1242/jcs.02970
57. Nielsen, K. R., Steffensen, R., Boegsted, M., Baech, J., Lundbye-Christensen, S., Hetland, M. L., et al. (2011). Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arth. Res. Therapy 13, R109. doi: 10.1186/ar3391
58. Nishikawa, K. C., and Millis, A. J. (2003). gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp. Cell Res. 287, 79-87.
59. Nyirkos, P., and Golds, E. E. (1990). Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem. J. 269, 265-268.
60. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.[see comment]. Cancer Cell 15, 220-231. doi: 10.1016/j.ccr.2009.01.027
61. Park, J. A., Drazen, J. M., and Tschumperlin, D. J. (2010). The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress. J. Biol. Chem. 285, 29817-29825. doi: 10.1074/jbc.M110.103416
62. Park, P. W., Reizes, O., and Bernfield, M. (2000). Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J. Biol. Chem. 275, 29923-29926. doi: 10.1074/jbc.R000008200
63. Pelloski, C. E., Mahajan, A., Maor, M., Chang, E. L., Woo, S., Gilbert, M., et al. (2005). YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. 11, 3326-3334. doi: 10.1158/1078-0432.CCR-04-1765 pp.3326-34
64. Perrin, R. J., Craig-Schapiro, R., Malone, J. P., Shah, A. R., Gilmore, P., Davis, A. E., et al. (2011). Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS ONE 6:e16032. doi: 10.1371/journal.pone.0016032
65. Persson, F., Rathcke, C. N., Gall, M. A., Parving, H. H., Vestergaard, H., and Rossing, P. (2012). High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 96, 84-89. doi: 10.1016/j.diabres.2011.12.008
66. Pini, M., Rhodes, D. H., Castellanos, K. J., Hall, A. R., Cabay, R. J., Chennuri, R., et al. (2012). Role of IL-6 in the resolution of pancreatitis in obese mice. J. Leukoc. Biol. 91, 957-966. doi: 10.1189/jlb.1211627
67. Pizano-Martinez, O., Yanez-Sanchez, I., Alatorre-Carranza, P., Miranda-Diaz, A., Ortiz-Lazareno, P. C., Garcia-Iglesias, T., et al. (2011). YKL-40 expression in CD14 liver cells in acute and chronic injury. World J. Gastroenterol. 17, 3830-3835. doi: 10.3748/wjg.v17.i33.3830
68. Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71-78. doi: 10.1038/nrc1256
69. Prince, R. N., Schreiter, E. R., Zou, P., Wiley, H. S., Ting, A. Y., Lee, R. T., et al. (2010). The heparin-binding domain of HB-EGF mediates localization to sites of cell-cell contact and prevents HB-EGF proteolytic release. J. Cell Sci. 123, 2308-2318. doi: 10.1242/jcs.058321
70. Qin, W., Zhu, W., Schlatter, L., Miick, R., Loy, T. S., Atasoy, U., et al. (2007). Increased expression of the inflammatory protein YKL-40 in precancers of the breast. Int. J. Cancer 121, 1536-1542. doi: 10.1002/ijc.22881
71. Rathcke, C. N., and Vestergaard, H. (2006). YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm. Res. 55, 221-227. doi: 10.1007/s00011-006-0076-y
72. Recklies, A. D., White, C., and Ling, H. (2002). The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem. J. 365, 119-126. doi: 10.1042/BJ20020075
73. Rehli, M., Krause, S. W., and Andreesen, R. (1997). Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43, 221-225. doi: 10.1006/geno.1997.4778
74. Rehli, M., Niller, H. H., Ammon, C., Langmann, S., Schwarzfischer, L., Andreesen, R., et al. (2003). Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J. Biol. Chem. 278, 44058-44067. doi: 10.1074/jbc.M306792200
75. Renkema, G. H., Boot, R. G., Au, F. L., Donker-Koopman, W. E., Strijland, A., Muijsers, A. O., et al. (1998). Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur. J. Biochem. 251, 504-509.
76. Roslind, A., Johansen, J. S., Junker, N., Nielsen, D. L., Dzaferi, H., Price, P. A., et al. (2007a). YKL-40 expression in benign and malignant lesions of the breast: a methodologic study. Appl. Immunohistochem. Mole. Morphol. 15, 371-381. doi: 10.1097/01.pai.0000213146.77772.6a
77. Roslind, A., Knoop, A. S., Jensen, M. B., Johansen, J. S., Nielsen, D. L., Price, P. A., et al. (2007b). YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res. Treat. 112, 275-285.
78. Saidi, A., Javerzat, S., Bellahcene, A., De Vos, J., Bello, L., Castronovo, V., et al. (2008). Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int. J. Cancer 122, 2187-2198. doi: 10.1002/ijc.23313
79. Scully, S., Yan, W., Bentley, B., Cao, Q. J., and Shao, R. (2011). Inhibitory activity of YKL-40 in mammary epithelial cell differentiation and polarization induced by lactogenic hormones: a role in mammary tissue involution. PLoS ONE 6:e25819. doi: 10.1371/journal.pone.0025819
80. Shackelton, L. M., Mann, D. M., and Millis, A. J. (1995). Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J. Biol. Chem. 270, 13076-13083. doi: 10.1074/jbc.270.22.13076
81. Shao, R., Cao, Q. J., Arenas, R. B., Bigelow, C., Bentley, B., and Yan, W. (2011). Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br. J. Cancer 105, 1203-1209. doi: 10.1038/bjc.2011.347
82. Shao, R., Hamel, K., Petersen, L., Cao, Q. J., Arenas, R. B., Bigelow, C., et al. (2009). YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28, 4456-4468. doi: 10.1038/onc.2009.292
83. Shibata, Y., Metzger, W. J., and Myrvik, Q. N. (1997). Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J. Immunol. 159, 2462-2467.
84. Stearman, R. S., Dwyer-Nield, L., Grady, M. C., Malkinson, A. M., and Geraci, M. W. (2008). A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res. 68, 34-43. doi: 10.1158/0008-5472.CAN-07-0988
85. Suzuki, T., Hashimoto, S., Toyoda, N., Nagai, S., Yamazaki, N., Dong, H. Y., et al. (2000). Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 96, 2584-2591.
86. Tsutsui, S., Yasuda, K., Suzuki, K., Tahara, K., Higashi, H., and Era, S. (2005). Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 14, 425-431.
87. Verhoeff, J. J., van Tellingen, O., Claes, A., Stalpers, L. J., van Linde, M. E., Richel, D. J., et al. (2009). Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:444. doi: 10.1186/1471-2407-9-444
88. Vind, I., Johansen, J. S., Price, P. A., and Munkholm, P. (2003). Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 38, 599-605.
89. Volck, B., Johansen, J. S., Stoltenberg, M., Garbarsch, C., Price, P. A., Ostergaard, M., et al. (2001). Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarth. Cart. 9, 203-214. doi: 10.1053/joca.2000.0377
90. Wang, H., Lathia, J. D., Wu, Q., Wang, J., Li, Z., Heddleston, J. M., et al. (2009). Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27, 2393-2404. doi: 10.1002/stem.188
91. Wen, P. Y., and Kesari, S. (2008). Malignant gliomas in adults. New Eng. J. Med. 359, 492-507. doi: 10.1056/NEJMra0708126
92. Wick, W., Weller, M., van den Bent, M., and Stupp, R. (2010). Bevacizumab and recurrent malignant gliomas: a European perspective. J. Clin. Oncol. 28, e188-189; author reply e190-182. doi: 10.1200/JCO.2009.26.9027